Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongnan Mo

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2018
Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal CarcinomaJing Huang, Binghe Xu, Hongnan Mo, et al.
Cancer Biology & Medicine|September 13, 2024
Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2- advanced breast cancerQi Zhao, Mingxia Jiang, Jiaxuan Liu, et al.
JAMA Network Open|November 2, 2022
Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast CancerHongnan Mo, Xiaoyan Yan, Fang Zhao, et al.
British Journal of Cancer|May 15, 2018
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 studyHongnan Mo, Jing Huang, Jiachen Xu, et al.
Nature Medicine|July 5, 2024
Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trialHongnan Mo, Yongpei Yu, Xiaoying Sun, et al.
Breast (Edinburgh, Scotland)|September 24, 2023
Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trialMaiyue He, Jiaxuan Liu, Zijing Wang, et al.
Cancer|December 4, 2018
Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in ChinaJing Huang, Hongnan Mo, Weilong Zhang, et al.
Therapeutic Advances in Medical Oncology|January 5, 2026
Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world studyXuenan Peng, Ruixia Song, Ying Fan, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 13, 2023
MTA1, a Novel ATP Synthase Complex Modulator, Enhances Colon Cancer Liver Metastasis by Driving Mitochondrial Metabolism ReprogrammingTing Wang, Fangzhou Sun, Chunxiao Li, et al.
International Journal of Cancer|June 27, 2020
Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in ChinaYimeng Chen, Yin Guan, Jiayu Wang, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2018
Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal CarcinomaJing Huang, Binghe Xu, Hongnan Mo, et al.
Cancer Biology & Medicine|September 13, 2024
Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2- advanced breast cancerQi Zhao, Mingxia Jiang, Jiaxuan Liu, et al.
JAMA Network Open|November 2, 2022
Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast CancerHongnan Mo, Xiaoyan Yan, Fang Zhao, et al.
British Journal of Cancer|May 15, 2018
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 studyHongnan Mo, Jing Huang, Jiachen Xu, et al.
Nature Medicine|July 5, 2024
Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trialHongnan Mo, Yongpei Yu, Xiaoying Sun, et al.
Breast (Edinburgh, Scotland)|September 24, 2023
Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trialMaiyue He, Jiaxuan Liu, Zijing Wang, et al.
Cancer|December 4, 2018
Promising efficacy of SHR-1210, a novel anti-programmed cell death 1 antibody, in patients with advanced gastric and gastroesophageal junction cancer in ChinaJing Huang, Hongnan Mo, Weilong Zhang, et al.
Therapeutic Advances in Medical Oncology|January 5, 2026
Efficacy and safety of PARP inhibitors in metastatic breast cancer patients with homologous recombination repair pathway gene mutations: a retrospective multicenter real-world studyXuenan Peng, Ruixia Song, Ying Fan, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|July 13, 2023
MTA1, a Novel ATP Synthase Complex Modulator, Enhances Colon Cancer Liver Metastasis by Driving Mitochondrial Metabolism ReprogrammingTing Wang, Fangzhou Sun, Chunxiao Li, et al.
International Journal of Cancer|June 27, 2020
Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in ChinaYimeng Chen, Yin Guan, Jiayu Wang, et al.
Pageof 6